Journal Article

Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants

Hupin, David, Paul, Stéphane, Waeckel, Louis, Vogrig, Manon, Haccourt, Alice, Bourlet, Thomas, Pozzetto, Bruno, Roche, Frederic, Botelho-Nevers, Elisabeth, Berger, Anne-Emmanuelle, Chanavat, Alice

2023

Overview

Reliable immunoassays are essential to early predict and monitor vaccine efficacy against SARS-CoV-2. The performance of an Interferon Gamma Release Assay (IGRA, QuantiFERON® SARS-CoV-2), and a current anti-spike serological test, compared to a plaque reduction neutralization test (PRNT) taken as gold standard were compared. Eighty vaccinated individuals, whose 16% had a previous history of COVID-19, were included in a longitudinal prospective study and sampled before and two to four weeks after each dose of vaccine. In non-infected patients, 2 doses were required for obtaining both positive IGRA and PRNT assays, while serology was positive after one dose. Each dose of vaccine significantly increased the humoral and cellular response. By contrast, convalescent subjects needed a single dose of vaccine to be positive on all 3 tests. Both IGRA and current serology assay were found predictive of a positive titer of neutralizing antibodies that is correlated with vaccine protection. Patients over 65 or 80 years old had a significantly reduced response. The response tended to be better with the heterologous scheme (vs. homologous) and with the mRNA-1273 vaccine (vs. BNT162b2) in the homologous group, in patients under 55 and under 65 years old, respectively. Finally, decrease intensity or absence of IGRA response and to a less extent of anti-spike serology were also correlated to reinfection which has occurred during the follow up. In conclusion, both IGRA and current anti-spike serology assays could be used at defined thresholds to monitor the vaccine response against SARS-CoV-2 and to simply identify non-responding individuals after a complete vaccination scheme. Capsule summary Two available specific tests (IGRA and anti-spike antibodies) could early assess the vaccine-induced immunity against SARS-CoV-2 at the individual scale, to potentially adapt the vaccination scheme in non-responder patients.

• Publisher: Springer US,Springer Verlag
• Subject: 2019-nCoV Vaccine mRNA-1273 / Aged / Aged, 80 and over / Antibodies, Neutralizing / Antibodies, Viral / Biomedical and Life Sciences / Biomedicine / BNT162 Vaccine / COVID-19 - prevention & control / COVID-19 infection / COVID-19 Vaccines / Emerging diseases / Human health and pathology / Humans / immunity / Immunity, Cellular / Immunity, Humoral / Immunology / Infectious Diseases / interferon-gamma / Internal Medicine / Life Sciences / Medical Microbiology / Microbiology and Parasitology / neutralization tests / Original / Original Article / Prospective Studies / SARS-CoV-2 / serology / Severe acute respiratory syndrome coronavirus 2 / Vaccination / vaccines / Vaccinology / Virology